European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

Reliable results with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Apr. 9, 2020 - Prof. Deepak Bhatt, MD

Better insight into current daily clinical practice and more collaboration is needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu

Why we need updated Diabetes Guidelines and new recommendations

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Policy recommendations to stimulate implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Cornelia Bala - European Diabetes Policy Summit

Implementation of guidelines: identifying barriers

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels

No significant effect of aspirin on dementia outcomes in patients with T2DM

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

Reduced CV outcomes with nonsteroidal MRA in patients with T2DM and mild-to-moderate CKD

News - Oct. 5, 2021

ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.

Nonsteroidal MRA reduces outcomes in T2DM across spectrum of kidney disease

News - Sep. 8, 2021

ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.

Significant increase of prevalence of diabetes among US adults from 1999 to 2018

Literature - Aug. 3, 2021 - Li Wang et al. - JAMA. 2021

This study showed that estimated age-standardized prevalence of diabetes among US adults increased significantly from 9.8% in 1999-2000 to 14.3% in 2017-2018. In 2015-2018, only 21.2% of adults with diagnosed diabetes achieved individualized HbA1C targets, BP <130/80 mmHg, and LDL-c <100 mg/dL.

Association between incident HF and T2DM-related microvascular disease

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

CV and renal events reduced by SGLT2i in routine clinical practice compared to DPP-4i in T2DM

News - July 1, 2021

ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.

New-onset AF reduced by nonsteroidal MRA in DKD patients

News - June 1, 2021

ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.

Reduction of CV events by dual SGLT1/2i in HF across full range of ejection fractions

News - May 26, 2021

ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.

CV outcome trial with nonsteroidal MRA meets primary end point in patients with DKD

News - May 11, 2021

In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.

Scientifc Statement from the AHA on adverse pregnancy outcomes and CVD

Literature - Apr. 21, 2021 - Parikh NI et al. - Circulation. 2021

Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

Diabetes and insulin resistance are strongest risk factors for premature onset of CHD in women

Literature - Feb. 11, 2021 - Dugani SB et al., - JAMA Cardiol. 2021

This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.